Cennerv lodges prelim offer documents for Catalist listing, to acquire US subsidiary with proceeds

Cennerv lodges prelim offer documents for Catalist listing, to acquire US subsidiary with proceeds

Michelle Zhu
21/09/18, 12:39 pm

SINGAPORE (Sept 21): Cennerv Pharmaceuticals on Wednesday lodged its preliminary prospectus ahead of its planned initial public offering (IPO) on the SGX Catalist board.

Cennerv is a Singapore-based pharmaceutical developer specialising in treatments for central nervous system (CNS) disorders with a focus on depression, insomnia, dementia, schizophrenia and autism.

The company intends to use a portion of its proceeds from the exercise to acquire a further 13 million units of Gemeni Therapeutics LLC, a US-based drug development company, for US$200,000 ($272, 700).

Details of the impending IPO, including the total number of shares to be offered under the placement and the issue price, have yet to be announced.

The company had earlier agreed to acquire 2 million units of Gemeni for US$20,000 in Feb this year.

Upon the acquisition of all 15 million units of Gemeni, Cennerv will own a 60% stake in the company, through which it intends to develop non-CNS assets in the US to diversify its current pipeline of CNS drug candidates.

According to the Cennerv’s preliminary offer document, its business model is to identify promising compounds that have shown efficacy in humans suffering from CNS disorders, or in relevant animal models of these particular disorders, from robust patent positions.

Cennerv intends to develop these compounds through to human Phase 2 clinical trials to prove efficacy in patients, before seeking to license out to bigger, more resource-rich pharma partners with the aim of bringing the compounds to the global markets.

As the company is in the midst of engaging in the development of its drug candidates, it has yet to monetise these drug candidates and therefore has no revenue generated from its loss-making financial periods spanning FY15 to 1Q18. 

Cennerv says that it however expects to eventually generate revenue from the eventual sale of drugs or licensing agreements, where it may earn upfront and milestone fees or market royalties.

“As our current portfolio of five drug candidates are at various stages of development, we believe that our drug candidates offer potential upfront licensing revenue when we sign such agreements for our more advanced drug candidates and our pre-clinical drug candidates may provide subsequent growth opportunities after further research and development,” said Cennerv in its product highlights sheet for its preliminary offer document.

Cennerv’s sole controlling shareholder is its chairman, Anil Kumar Ratty, who also has deemed interest Cennerv held his 50.2%-owned company Chakra Biotech, and his wife Sawarn Kaur D/O Hari Singh.

US sanctions on Huawei could backfire

SINGAPORE (May 27): It was only to have been expected. After nearly a year of pressure that failed to stop Huawei Technologies Co’s expansion -- especially in the rollout of the next generation 5G wireless network globally -- in its tracks, US President Donald Trump signed an executive order effectively barring American firms from doing business with the Chinese telecommunications equipment company. The inclusion of Huawei on the US Department of Commerce’s Bureau of Industry and Security’s (BIS) Entity List means that companies would need to apply for a waiver to supply goods with 25....

Annica chairman Ong quits just as $33 mil goes missing at his law firm JLC

SINGAPORE (May 27): Jeffrey Ong, managing partner of law firm JLC Advisors, may have given instructions to pay out a sum of $33.2 million held in escrow by his firm for a client, Allied Technologies. According to Allied’s statement filed with Singapore Exchange on May 23, the payment may have been “unauthorised”, citing a letter it received from JLC on May 22. Allied’s statement did not specify who the payment was made to. Ong also abruptly resigned as non-executive chairman of Annica Holdings on May 20. In a May 22 filing with SGX, Annica CEO Sandra Liz Hon Ai Ling said Ong resigne....

SGX RegCo sees targeted approach in enforcement, more powerful market discipline

SINGAPORE (May 27): Tan Boon Gin, CEO of stock exchange regulator Singapore Exchange Regulation, says the market can expect a stronger regulatory presence. “You will see a series of enforcement cases coming up quite soon,” he tells The Edge Singapore. Tan’s assertion comes amid significant changes in the market as sentiment remains lacklustre and investors’ expectations change. The local stock market has gone through significant upheaval, not least because of the penny stock crash in 2013 that wiped out some $8 billion in value from the market. The event dented investor sentiment, a....